<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00321906</url>
  </required_header>
  <id_info>
    <org_study_id>14467B</org_study_id>
    <nct_id>NCT00321906</nct_id>
  </id_info>
  <brief_title>Comparison of Sirolimus and Azathioprine in Lung Transplantation</brief_title>
  <official_title>Comparison of a Tacrolimus/Sirolimus/Prednisone Regimen Versus Tacrolimus/Azathioprine/Prednisone Immunosuppressive Regimen in Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of two different
      anti-rejection drug regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multicenter prospective, randomized controlled clinical trial compared the open label
      use of sirolimus with that of azathioprine in a tacrolimus-based immunosuppression regimen.
      Eligible patients were identified during a 90-day screening period immediately after
      transplantation and randomized via a computer-generated scheme. Patient randomization was
      stratified according to center and rejection status in the first 90 days after
      transplantation. All patients received IL-2 receptor antagonist induction therapy,
      tacrolimus, azathioprine, and corticosteroids until 90 days after transplantation. At 90 days
      after transplantation, patients were randomized at a 1:1 ratio to either continue
      azathioprine or change from azathioprine to sirolimus.

      The dosing and levels of immunosuppressive medications were standardized for all patients
      included in this study. Tacrolimus was dosed at 0.04 mg/kg twice daily with target trough
      levels between 5 and 15 ng/ml, azathioprine was administered at 2 mg/kg daily with dose
      adjustments for leukopenia, sirolimus was initially dosed at 2 mg/day with target trough
      levels between 5 and 15 ng/ml, and prednisone was tapered to not more than 10 mg/day by 3
      months after transplantation. All patients received induction therapy with either daclizumab
      or basiliximab as per the product package insert.

      In addition, prophylactic antimicrobials were standardized among the participating sites. All
      patients with either donor and/or recipient cytomegalovirus (CMV)-positive serostatus
      received either intravenous ganciclovir or oral valganciclovir for a total of 90 days. Lung
      transplant recipients who were negative for both donor and recipient CMV serostatus received
      valacyclovir for 90 days. Antifungal prophylaxis was determined by each site. Pneumocystis
      jiroveci prophylaxis was continued throughout the study. Lipid-lowering medications were
      recommended according to the National Cholesterol Education Program guidelines.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute Rejection Rate at 12 Months</measure>
    <time_frame>12mos</time_frame>
    <description>Raw proportion of patients that experienced acute rejection at or before 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Rejection-free Survival at 12 Months</measure>
    <time_frame>12 mos</time_frame>
    <description>Kaplan-Meier estimate of proportion of patients that had not experienced acute rejection by 12 months. Acute rejection is defined as rejection at any of the following grades.
Grade A0 - None With/Without Grade A1 - Minimal Grade A2 - Mild Grade A3 - Moderate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Acute Rejection at 12 Months</measure>
    <time_frame>12 mos</time_frame>
    <description>Raw proportion of patients that experienced rejection at or above grade A2 by 12 months.
Grade A0 - None With/Without Grade A1 - Minimal Grade A2 - Mild Grade A3 - Moderate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchiolitis Obliterans Syndrome (BOS) at 24 Months</measure>
    <time_frame>24 mos</time_frame>
    <description>Kaplan-Meier estimate of proportion of patients that had not experienced BOS by 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchiolitis Obliterans Syndrome (BOS) at 36 Months</measure>
    <time_frame>36 mos</time_frame>
    <description>Kaplan-Meier estimate of proportion of patients that had not experienced BOS by 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 12 Months</measure>
    <time_frame>12 mos</time_frame>
    <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 24 Months</measure>
    <time_frame>24 mos</time_frame>
    <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at 36 Months</measure>
    <time_frame>36 mos</time_frame>
    <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 36 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Delayed Graft Function</condition>
  <condition>Acute Graft Rejection</condition>
  <arm_group>
    <arm_group_label>Azathioprine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(tacrolimus,azathioprine/prednisone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tacrolimus/sirolimus/prednisone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azathioprine</intervention_name>
    <description>azathioprine 2mg/kg</description>
    <arm_group_label>Azathioprine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <description>sirolimus 2-4mg daily</description>
    <arm_group_label>Sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Lung transplant recipients between the age of 18 and 65 years of age.

          -  Females who are capable of becoming pregnant must have a negative pregnancy test prior
             to consent. (Females of childbearing potential must be using a medically acceptable
             method of birth control for the duration of the study.)

          -  All patients must be able to give written informed consent.

        Exclusion Criteria:

          -  White blood cell count (WBC) &lt; 4.0/mm3

          -  Platelet count &lt; 100,000/mm3

          -  Severe hypercholesterolemia (&gt; 350 mg/dl) or hypertriglyceridemia (&gt; 500 mg/dl)

          -  Uncontrolled systemic infection at the time of consent.

          -  Previous organ transplant

          -  Treatment with a drug within the last 30 days that has not received regulatory
             approval at the time of study entry or for the duration of the study (3 years).

          -  Use of maintenance immunosuppression other than daclizumab, tacrolimus, azathioprine,
             or prednisone prior to randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward Garrity, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Bhorade S, Ahya VN, Baz MA, Valentine VG, Arcasoy SM, Love RB, Seethamraju H, Alex CG, Bag R, Deoliveira NC, Husain A, Vigneswaran WT, Charbeneau J, Krishnan JA, Durazo-Arvizu R, Norwick L, Garrity E. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. Am J Respir Crit Care Med. 2011 Feb 1;183(3):379-87. doi: 10.1164/rccm.201005-0775OC. Epub 2010 Sep 10.</citation>
    <PMID>20833822</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 2, 2006</study_first_submitted>
  <study_first_submitted_qc>May 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2006</study_first_posted>
  <results_first_submitted>December 17, 2013</results_first_submitted>
  <results_first_submitted_qc>December 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2014</results_first_posted>
  <last_update_submitted>September 19, 2016</last_update_submitted>
  <last_update_submitted_qc>September 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rejection in lung transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delayed Graft Function</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Azathioprine</title>
          <description>(tacrolimus,azathioprine/prednisone)</description>
        </group>
        <group group_id="P2">
          <title>Sirolimus</title>
          <description>tacrolimus/sirolimus/prednisone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Azathioprine</title>
          <description>(tacrolimus,azathioprine/prednisone)</description>
        </group>
        <group group_id="B2">
          <title>Sirolimus</title>
          <description>tacrolimus/sirolimus/prednisone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="94"/>
            <count group_id="B2" value="87"/>
            <count group_id="B3" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="52" upper_limit="62"/>
                    <measurement group_id="B2" value="57" lower_limit="48" upper_limit="60"/>
                    <measurement group_id="B3" value="57" lower_limit="50" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Acute Rejection Rate at 12 Months</title>
        <description>Raw proportion of patients that experienced acute rejection at or before 12 months.</description>
        <time_frame>12mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine</title>
            <description>(tacrolimus,azathioprine/prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>tacrolimus/sirolimus/prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Rejection Rate at 12 Months</title>
          <description>Raw proportion of patients that experienced acute rejection at or before 12 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Rejection-free Survival at 12 Months</title>
        <description>Kaplan-Meier estimate of proportion of patients that had not experienced acute rejection by 12 months. Acute rejection is defined as rejection at any of the following grades.
Grade A0 - None With/Without Grade A1 - Minimal Grade A2 - Mild Grade A3 - Moderate</description>
        <time_frame>12 mos</time_frame>
        <population>The analysis population included patients who underwent at least one transbronchial biopsy.</population>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine</title>
            <description>(tacrolimus,azathioprine/prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>tacrolimus/sirolimus/prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Rejection-free Survival at 12 Months</title>
          <description>Kaplan-Meier estimate of proportion of patients that had not experienced acute rejection by 12 months. Acute rejection is defined as rejection at any of the following grades.
Grade A0 - None With/Without Grade A1 - Minimal Grade A2 - Mild Grade A3 - Moderate</description>
          <population>The analysis population included patients who underwent at least one transbronchial biopsy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Acute Rejection at 12 Months</title>
        <description>Raw proportion of patients that experienced rejection at or above grade A2 by 12 months.
Grade A0 - None With/Without Grade A1 - Minimal Grade A2 - Mild Grade A3 - Moderate</description>
        <time_frame>12 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine</title>
            <description>(tacrolimus,azathioprine/prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>tacrolimus/sirolimus/prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Acute Rejection at 12 Months</title>
          <description>Raw proportion of patients that experienced rejection at or above grade A2 by 12 months.
Grade A0 - None With/Without Grade A1 - Minimal Grade A2 - Mild Grade A3 - Moderate</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchiolitis Obliterans Syndrome (BOS) at 24 Months</title>
        <description>Kaplan-Meier estimate of proportion of patients that had not experienced BOS by 24 months.</description>
        <time_frame>24 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine</title>
            <description>(tacrolimus,azathioprine/prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>tacrolimus/sirolimus/prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchiolitis Obliterans Syndrome (BOS) at 24 Months</title>
          <description>Kaplan-Meier estimate of proportion of patients that had not experienced BOS by 24 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bronchiolitis Obliterans Syndrome (BOS) at 36 Months</title>
        <description>Kaplan-Meier estimate of proportion of patients that had not experienced BOS by 36 months.</description>
        <time_frame>36 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine</title>
            <description>(tacrolimus,azathioprine/prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>tacrolimus/sirolimus/prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Bronchiolitis Obliterans Syndrome (BOS) at 36 Months</title>
          <description>Kaplan-Meier estimate of proportion of patients that had not experienced BOS by 36 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at 12 Months</title>
        <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 12 months.</description>
        <time_frame>12 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine</title>
            <description>(tacrolimus,azathioprine/prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>tacrolimus/sirolimus/prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 12 Months</title>
          <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 12 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at 24 Months</title>
        <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 24 months.</description>
        <time_frame>24 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine</title>
            <description>(tacrolimus,azathioprine/prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>tacrolimus/sirolimus/prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 24 Months</title>
          <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 24 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at 36 Months</title>
        <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 36 months.</description>
        <time_frame>36 mos</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Azathioprine</title>
            <description>(tacrolimus,azathioprine/prednisone)</description>
          </group>
          <group group_id="O2">
            <title>Sirolimus</title>
            <description>tacrolimus/sirolimus/prednisone</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at 36 Months</title>
          <description>Kaplan-Meier estimate of proportion of patients that survived to (i.e., had not died by) 36 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="87"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years post-transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Azathioprine</title>
          <description>(tacrolimus,azathioprine/prednisone)</description>
        </group>
        <group group_id="E2">
          <title>Sirolimus</title>
          <description>tacrolimus/sirolimus/prednisone</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia/Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Love</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Eyelash infection</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency or increased creatinine level</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Malignancy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Fear of handshakes</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Declining pulmonary function</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia/Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Excess bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Persistent acute rejection</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pedal edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidemia</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Severe hypertriglyceridemia (.500 mg/dl)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal insufficiency or increased creatinine level</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Declining pulmonary function</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Bronchial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="87"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="87"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Edward Garrity, MD</name_or_title>
      <organization>The University of Chicago</organization>
      <phone>(773) 834-1119</phone>
      <email>egarrity@uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

